America Is Celebrating a 13% Drop in Overdoses. The UN Just Counted 331 Million People Using Drugs Worldwide.

On June 26 — the same week America was absorbing good news about declining overdose deaths — the United Nations Office on Drugs and Crime released its World Drug Report 2026 with a different set of numbers. In 2024, 331 million people used drugs globally. That’s 1 in 16 people on earth. It’s a 34% increase from ten years ago. Cocaine production rose 370% between 2014 and 2024.

America is celebrating its declining overdose numbers while the world’s drug supply just grew by a third. Those two facts live in the same paragraph.

The domestic progress is real. The CDC’s preliminary data shows 69,147 drug overdose deaths in the 12 months ending January 2026 — a 13.2% decline from the prior year, a genuine signal that naloxone distribution, expanded MOUD access, and harm reduction are bending the curve. Cheer that. It represents tens of thousands of people who are alive this June who would not have been.

What the domestic numbers don’t capture is the global production surge that is the upstream condition. Cocaine supply at record levels means cocaine prices fall, potency rises, and the drug reaches into communities and demographics that were previously priced out. Fentanyl potency has reportedly dropped in the U.S. market as Chinese precursor controls bite — one major factor in the overdose decline. But precursor chemistry is adaptive. What goes down in potency can come back up when manufacturers find another route.

The UN report breaks down the 331 million by substance: cannabis users account for 256 million; opioids affect 63 million globally; amphetamines 32 million; cocaine 25 million; ecstasy 21 million. These are not American numbers. But they describe the industrial scale at which the substances Americans are recovering from are being produced and distributed.

For the providers, case managers, and advocates in Arizona reading this: the next patient you see who is new to cocaine, or escalating, is encountering a drug whose global supply chain just expanded to a scale not seen in recorded history. The 13% U.S. overdose decline is a victory worth naming. It is not a reason to believe the structural problem is resolving.

The supply is not a moral failure. It is an economic system. Understanding it as such is the precondition for responding to it effectively.